- Home
- SRAD vs RYTM Comparison
SRAD vs RYTM Comparison
Compare SRAD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | RYTM |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.8B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SRAD | RYTM |
|---|---|---|
| Price | $13.35 | $85.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $29.50 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 3.9M | 721.7K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.03 | $55.34 |
| Revenue Next Year | $14.81 | $86.06 |
| P/E Ratio | $49.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.69 | $55.31 |
| 52 Week High | $32.22 | $122.20 |
Technical Indicators
Market Signals| Indicator | SRAD | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 46.56 |
| Support Level | N/A | $82.98 |
| Resistance Level | $19.55 | $90.79 |
| Average True Range (ATR) | 1.29 | 3.49 |
| MACD | -0.35 | 0.26 |
| Stochastic Oscillator | 24.60 | 34.74 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.